Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Shah, N. P.; Kim, D.-W.; Kantarjian, H.; Rousselot, P.; Llacer, P. E. D.; Enrico, A.; Vela-Ojeda, J.; Silver, R. T.; Khoury, H. J.; Muller, M. C.; Lambert, A.; Matloub, Y.; Hochhaus, A.

期刊名称Haematologica
作者Shah, N. P.; Kim, D.-W.; Kantarjian, H.; Rousselot, P.; Llacer, P. E. D.; Enrico, A.; Vela-Ojeda, J.; Silver, R. T.; Khoury, H. J.; Muller, M. C.; Lambert, A.; Matloub, Y.; Hochhaus, A.
卷第95卷
期第2期
印刷ISSN0390-6078
电子ISSN1592-8721
文件大小279.48KB
发表时间2010-02-01
DOI10.3324/haematol.2009.011452
页码232-240

发现好书期刊，享受阅读乐趣

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib